Vonapanitase

Drug Profile

Vonapanitase

Alternative Names: PRT 201

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Proteon Therapeutics
  • Class Elastases; Recombinant proteins
  • Mechanism of Action Extracellular matrix protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Vascular disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Vascular disorders
  • Phase I Peripheral arterial disorders

Most Recent Events

  • 08 Nov 2017 Phase-I development is ongoing in USA (NCT02956993; 9226509)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Peripheral-arterial-disorders in USA (Intra-arterial, Injection)
  • 10 May 2017 Vonapanitase receives Breakthrough Therapy status for Vascular disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top